STOCK TITAN
  1. Home
  2. News
  3. COLL

Collegium Pharmaceutical Inc - COLL STOCK NEWS

Welcome to our dedicated news page for Collegium Pharmaceutical (Ticker: COLL), a resource for investors and traders seeking the latest updates and insights on Collegium Pharmaceutical.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Collegium Pharmaceutical's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Collegium Pharmaceutical's position in the market.

News
Collegium Announces Authorized Generic Agreement with Hikma Pharmaceuticals USA Inc. for Nucynta® and Nucynta® ER
Rhea-AI Summary

Collegium Pharmaceutical, Inc. (Nasdaq: COLL) has announced an authorized generic agreement with Hikma Pharmaceuticals USA Inc. for Nucynta® and Nucynta® ER, bolstering the value of the Nucynta Franchise through 2025 and beyond. Collegium will manufacture and supply Hikma with authorized generic products, with Hikma having exclusive rights to sell them in the U.S. Collegium will receive a share of net profits based on the number of generic entrants.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
-
News
Collegium to Report First Quarter 2024 Financial Results on May 9, 2024
Rhea-AI Summary
Collegium Pharmaceutical, Inc. (Nasdaq: COLL) will report its first quarter 2024 financial results on May 9, 2024, after the market closes. The company aims to improve the lives of individuals with severe medical conditions. A live conference call and webcast will follow the financial report at 4:30 p.m. ET on the same day.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.01%
Tags
conferences earnings
-
News
Collegium Pharmaceutical, Inc. Announces Redemption of Outstanding 2.625% Convertible Senior Notes Due 2026
Rhea-AI Summary
Collegium Pharmaceutical, Inc. announces the redemption of $26,350,000 aggregate principal amount of its outstanding 2.625% Convertible Senior Notes Due 2026, with a redemption price of approximately $1,008.68 per $1,000 principal amount of Notes. The redemption is triggered by the last reported sale price of the Company's Common Stock exceeding 130% of the conversion price of the Notes.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.21%
Tags
none
News
Collegium to Participate in 23rd Annual Needham Virtual Healthcare Conference
Rhea-AI Summary
Collegium Pharmaceutical, Inc. (COLL) will participate in a fireside chat at the 23rd Annual Needham Healthcare Conference on April 10, 2024. The event will be webcast live and accessible from the Company's website.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.73%
Tags
conferences
-
News
Collegium Reports Record Fourth Quarter and Full-Year 2023 Financial Results
Rhea-AI Summary
Collegium Pharmaceutical, Inc. reported record quarterly and full-year net revenue, achieved GAAP net income, and delivered record adjusted EBITDA. The company ended 2023 with strong financials and cash reserves. Business highlights include growth in prescriptions, share repurchase programs, and contract renegotiations. The company reaffirms its full-year 2024 guidance for product revenues, net, adjusted operating expenses, and adjusted EBITDA. Financial results for the quarter and year ended December 31, 2023, show significant increases in net revenue, GAAP net income, and adjusted EBITDA compared to the previous year.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
10.79%
Tags
earnings
-
News
Collegium to Report Fourth Quarter and Full-Year 2023 Financial Results on February 22, 2024
Rhea-AI Summary
Collegium Pharmaceutical, Inc. (Nasdaq: COLL) will report Q4 and full-year 2023 financial results on February 22, 2024. A live conference call and webcast will follow. The Company is focused on improving the lives of people with serious medical conditions.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.39%
Tags
conferences earnings
News
Collegium Provides 2024 Financial Guidance
Rhea-AI Summary
Collegium Pharmaceutical, Inc. (Nasdaq: COLL) expects product revenues of $580.0 million to $595.0 million, adjusted operating expenses of $120.0 million to $125.0 million, and adjusted EBITDA of $380.0 million to $395.0 million in 2024. The company also authorized a $150.0 million share repurchase program. Collegium's 2023 financial performance was strong, with over 20% revenue growth and over 35% adjusted EBITDA growth compared to 2022. The company returned $75.0 million in capital to shareholders in 2023 and renegotiated major contracts for its products, positioning it for growth in 2024.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
8.42%
Tags
none
-
News
Appeals Court Upholds PTAB’s Finding of Invalidity of Purdue’s 961 Patent
Rhea-AI Summary
Collegium Pharmaceutical, Inc. (Nasdaq: COLL) announced that the U.S. Court of Appeals for the Federal Circuit upheld the judgment of the Patent Trial and Appeal Board (PTAB) in its final decision that Purdue’s ‘961 patent, which Purdue has claimed is infringed by Xtampza® ER, is invalid. The Federal Circuit’s decision confirms both that the PTAB had statutory authority to issue its final decision, and that the PTAB did correctly conclude that the ʼ961 patent was invalid.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.69%
Tags
none
-
News
Collegium Announces $25 Million Accelerated Share Repurchase Program
Rhea-AI Summary
COLL: Collegium Pharmaceutical Announces $25 Million Accelerated Share Repurchase Agreement with Jefferies LLC, part of $100 million share repurchase program. President and CEO Joe Ciaffoni highlights record financial performance and commitment to returning value to shareholders.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
5.58%
Tags
buyback
News
Collegium to Participate in Upcoming Investor Conferences
Rhea-AI Summary
Collegium Pharmaceutical, Inc. (Nasdaq: COLL) to participate in investor conferences. Fireside chats at Jefferies 14th Annual Global Healthcare Conference on Nov 14 and Piper Sandler 35th Annual Healthcare Conference on Nov 28. Webcast available on company website.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
6.6%
Tags
conferences
Stock COLL logo
Collegium Pharmaceutical Inc

Nasdaq:COLL

COLL Rankings

#2292 Ranked by Market Cap
#986 Ranked by Stock Gains
N/A Ranked by Dividends

COLL Stock Data

1.17B
28.80M
1.41%
122.63%
21.76%
Pharmaceutical Preparation Manufacturing
Manufacturing
Link
US
Stoughton

About COLL

collegium pharmaceutical, inc. is a specialty pharmaceutical company developing and planning to commercialize next generation, abuse-deterrent products for the treatment of patients suffering from chronic pain and other diseases. with a substantial number of patients suffering from chronic pain, collegium is committed to developing and commercializing a portfolio of products that address the growing problems associated with non-medical use, abuse and misuse of prescription products by leveraging the company’s proprietary deterx® technology platform. deterx technology can be used with drugs that are commonly abused such as opioids and amphetamines, as well as drugs that have a narrow therapeutic index that would benefit from protection against misuse such as breaking, crushing, grinding, or dissolving the product. the deterx technology platform is covered by u.s. and international patents and patent applications. collegium’s lead product candidate, xtampza er™, is an abuse-deterrent, ex